Therapeutic DNA plasmid vaccine encoding HPV16 E6/E7/L2 fused to calreticulin; delivered intramuscularly to enhance antigen processing/presentation and elicit HPV16-specific CD8+ and CD4+ T-cell responses. Doses: 0.3, 1, or 3 mg at weeks 0, 4, and 8.
Naked DNA plasmid encoding HPV16 E6/E7/L2 fused to calreticulin; after intramuscular delivery (with electroporation), host cells express the fusion antigen, and calreticulin enhances antigen processing and MHC class I presentation. This elicits HPV16-specific CD8+ and CD4+ T-cell responses and induces L2-neutralizing antibodies, promoting lysis of HPV16-expressing cells and potentially preventing new HPV infections.
YES
INDIRECT
DNA vaccine expresses HPV16 E6/E7/L2 and enhances MHC I presentation, inducing E6-specific CD8+ T cells that recognize E6 peptides on target cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ T-cell help).
Therapeutic DNA plasmid vaccine encoding HPV16 E6/E7/L2 fused to calreticulin; delivered intramuscularly to enhance antigen processing/presentation and elicit HPV16-specific CD8+ and CD4+ T-cell responses. Doses: 0.3, 1, or 3 mg at weeks 0, 4, and 8.
Naked DNA plasmid encoding HPV16 E6/E7/L2 fused to calreticulin; after intramuscular delivery (with electroporation), host cells express the fusion antigen, and calreticulin enhances antigen processing and MHC class I presentation. This elicits HPV16-specific CD8+ and CD4+ T-cell responses and induces L2-neutralizing antibodies, promoting lysis of HPV16-expressing cells and potentially preventing new HPV infections.
YES
INDIRECT
Vaccination induces HPV16 E7–specific CD8+ T cells via MHC I presentation; these CTLs recognize E7 peptides on target cells and kill them through perforin/granzyme-mediated apoptosis.
Therapeutic DNA plasmid vaccine encoding HPV16 E6/E7/L2 fused to calreticulin; delivered intramuscularly to enhance antigen processing/presentation and elicit HPV16-specific CD8+ and CD4+ T-cell responses. Doses: 0.3, 1, or 3 mg at weeks 0, 4, and 8.
Naked DNA plasmid encoding HPV16 E6/E7/L2 fused to calreticulin; after intramuscular delivery (with electroporation), host cells express the fusion antigen, and calreticulin enhances antigen processing and MHC class I presentation. This elicits HPV16-specific CD8+ and CD4+ T-cell responses and induces L2-neutralizing antibodies, promoting lysis of HPV16-expressing cells and potentially preventing new HPV infections.
NO
INDIRECT
This DNA vaccine mainly induces neutralizing antibodies against L2 to block HPV infection; cytotoxic T-cell killing is directed primarily at E6/E7-expressing cells, not at L2-expressing cells.
IV humanized anti-CD19 monoclonal antibody that binds CD19 on malignant B cells, inducing antibody-dependent cellular cytotoxicity/phagocytosis and direct cytotoxic signaling.
Humanized anti-CD19 monoclonal antibody that binds CD19 on malignant B cells, inducing antibody-dependent cellular cytotoxicity and phagocytosis and promoting direct cytotoxic/apoptotic signaling.
YES
DIRECT
Binds CD19 on B cells and recruits FcγR-expressing immune effectors to kill via ADCC and antibody-dependent phagocytosis; can also trigger pro-apoptotic signaling in CD19+ cells.
Oral BCL-2 inhibitor (BH3 mimetic) that blocks BCL-2 to trigger mitochondrial apoptosis.
Selective oral BCL-2 inhibitor (BH3 mimetic) that binds the hydrophobic groove of BCL-2, neutralizes its anti-apoptotic function, restores mitochondrial outer membrane permeabilization, and triggers caspase-mediated apoptosis in BCL-2–dependent tumor cells; spares BCL-XL.
YES
DIRECT
Venetoclax is a BH3-mimetic that binds and inhibits BCL-2, displacing pro-apoptotic factors to activate BAX/BAK, induce mitochondrial outer membrane permeabilization, and trigger caspase-dependent apoptosis in BCL-2–dependent cells.